Bavarian Nordic to Host First Quarter 2012 Results Conference Call
KVISTGAARD, Denmark - May 14, 2012 - Bavarian Nordic A/S (OMX: BAVA) will
announce its 2012 first quarterly results on Tuesday, May 22, 2012.
The company will host a conference call at 2:00 pm CET (8:00 am EDT) on the same
day. Anders Hedegaard, President and CEO, will give a short presentation
followed by a Q&A session. Additional participants from Bavarian Nordic are Paul
Chaplin, Executive Vice President and Division President Infectious Diseases,
Reiner Laus, Executive Vice President and Division President Cancer Vaccines,
Ole Larsen, CFO and Rolf Sass SÃ¸rensen, Vice President Investor Relations.
Dial-in numbers for the conference call are: UK: +44 (0)207 1620 177, US:
+1 334 323 6203, Denmark: +45 3271 4611. Please state conference ID: 916860.
For additional details please visit http://www.bavarian-nordic.com/q1 where also
the accompanying presentation will be available in advance of the conference
A recording of the conference call will be available from the company's website
during the same day.
Rolf Sass SÃ¸rensen, Vice President Investor Relations & Communications
Phone: +45 33 26 83 83
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVACÂ®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVACÂ® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNEÂ®, a third-generation smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE